Feed VRTX
VR

Vertex Pharmaceuticals

VRTX · NASDAQ

$508.14 -1.86% (-$9.61)
1M -4.43%
Market Cap $131.0B
P/E Ratio 29.75x
Div. Yield -
ROE 23.31%

Bulios Fair Price

$379.3

25.4% downside

Trenutna cena

$508.14

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica VRTX trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Moderate
5/9
Valuation
22 /100
Expensive
EV/EBITDA 23.30x
P/S 10.38x
P/B 6.47x
Growth
46 /100
Stable
Rev. growth 10.58%
FCF growth 6.64%
Book val. growth 10.29%
Profitability
100 /100
Strong
Net margin 34.89%
Op. margin 38.59%
FCF margin 30.07%
Quality
86 /100
Excellent
ROE 23.31%
ROA 16.06%
Asset turnover 0.46x
Debt
100 /100
Low
Current ratio 3.19x
Int. coverage 800.23x
Net debt/EBITDA -0.77x
Stability
41 /100
Moderate
Rev. volatility 1.05%
EPS volatility 517.44%
Profitable years 1

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o VRTX
Online

O podjetju

Vertex Pharmaceuticals (VRTX) is a leading biopharmaceutical company specializing in the development of drugs for the treatment of rare and severe diseases. Their primary focus is on the development of innovative therapies for patients with cystic fibrosis, a genetic disorder affecting the respiratory and digestive systems. Vertex Pharmaceuticals is at the forefront of gene therapy and molecular-based treatments. Vertex Pharmaceuticals stock is suitable for investors interested in the pharmaceutical sector and investments in the treatment of rare diseases. Add Vertex Pharmaceuticals stock to your watchlist on Bulios and be the first to receive updates on new medical breakthroughs and the development of therapies from this prominent company.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Reshma Kewalramani

Employees

6,400

Headquarters

Boston

Prihajajoči dogodki

02 NOV.

Earnings

Upcoming earnings report

44d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.